 Deciphera Pharmaceuticals, Inc. NASDAQ:DCPH, today announced that the Journal of Clinical Oncology has published results from its Phase 1 study of QINLOCK, the Companys switch-control tyrosine kinase inhibitor, in patients with second-line through fourth-line plus gastrointestinal stromal tumor GIST. The article, entitled Switch control inhibition of KIT and PDGFRA in patients with advanced gastrointestinal stromal tumor GIST: a phase 1 study of ripretinib, is now available online and will be published in a future print issue of Journal of Clinical Oncology. 